Young-Jin Kim is the Chairman and CEO of Handok Inc., one of South Korea's leading pharmaceutical companies, and serves as a Board Member and Director at Rezolute Inc.( He joined Handok in 1984 and held early career positions at Hoechst AG in Frankfurt, Germany between 1984 and 1986( From 1991 to 2005, Kim served as CEO of Roussel Korea, Hoechst Marion Roussel Korea, and Aventis Pharma Korea, while also serving as Country Manager for Hoechst AG and Aventis in Korea from 1996 to 2005( He was appointed CEO of Handok in 1996(

Kim holds an M.B.A. from the Kelley School of Business at Indiana University (1984) and completed the Advanced Management Program at Harvard Business School (1996)( Beyond his primary role at Handok, he has served as President of the Handok Jeseok Foundation since 2014, President of the Korean-German Society (KDG) since 2010, and Vice President of the Medium Industries Committee of the Korea Chamber of Commerce & Industry since 2009( At Rezolute, Kim has demonstrated significant investment conviction, investing $9 million in the biotech company between June 2024 and June 2025, representing over 5% of the company's market capitalization( He also serves on the Board of Directors of Genexine Inc.(

Written by Perplexity from public sources.

Filings come from SEC EDGAR. Not investment advice.